One step towards restoration of self-tolerance in human autoimmune diseases

Médecine sciences : M/S
Lucienne Chatenoud

Abstract

In developed countries the incidence of autoimmune insulin-dependent or type 1 diabetes as the one of all autoimmune diseases has steadily increased over the last decades. Conventional therapy of type 1 diabetes is essentially palliative namely, chronic delivery of exogenous insulin that is associated with major constraints (multiple daily parenteral administration, serious risks linked to hypoglycemic episodes) and incomplete effectiveness in preventing severe degenerative complications. This explains the growing attention on modern therapeutic strategies using biological agents such as CD3 monoclonal antibodies that allow 'reprogramming' the immune system to restore self-tolerance to pancreatic beta cell antigens. This strategy which proved successful in the experimental setting has recently been translated to the clinic with very encouraging results. CD3 antibodies may represent a new category of drugs affording a real cure for autoimmunity namely, inhibiting the pathogenic immune response while preserving the host reactivity to unrelated antigens.

References

Jan 1, 1992·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J TimsitC Boitard
Aug 8, 1985·The New England Journal of Medicine·Ortho Multicenter Transplant Study Group
Mar 1, 1988·European Journal of Immunology·R Yasunami, J F Bach
Jan 1, 1988·Annual Review of Immunology·H CleversC Terhorst
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·L ChatenoudJ F Bach
Apr 1, 1996·Arthritis and Rheumatism·M L BarnettD E Trentham
Feb 12, 1998·The Journal of Experimental Medicine·J TianD L Kaufman
Jun 24, 1998·Transplantation Proceedings·E S WoodleJ R Thistlethwaite
Sep 30, 1998·Diabetes·S M SingerH O McDevitt
Nov 28, 2001·Immunological Reviews·L ChatenoudJeffrey A Bluestone
May 31, 2002·The New England Journal of Medicine·Diabetes Prevention Trial--Type 1 Diabetes Study Group
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Feb 4, 2003·Nature Reviews. Immunology·Lucienne Chatenoud
Mar 27, 2003·Nature Reviews. Immunology·Jean-François Bach, Jean François Bach
Oct 3, 1953·Nature·R E BILLINGHAMP B MEDAWAR
Jan 30, 2004·Diabetes·Chynna SteeleKevan C Herold
Feb 1, 2005·Annals of the New York Academy of Sciences·Berrin Ergun-LongmireNoel K Maclaren
Apr 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam P KohmStephen D Miller
Dec 2, 2005·International Reviews of Immunology·Mireia Sospedra, Roland Martin
Nov 30, 2006·Annals of the New York Academy of Sciences·Dana EliasItamar Raz

Related Concepts

Teplizumab
Monoclonal Antibodies
Autoantibodies
Autoantigens
Autoimmune Diseases
Diabetes, Autoimmune
Glutamate Decarboxylase
Polyglobin
Immunotherapy
Novolin

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.